

(19)



(11)

EP 4 188 377 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):

A61K 31/4706 ^(2006.01) **A61K 31/155** ^(2006.01)
A61K 31/366 ^(2006.01) **A61K 31/40** ^(2006.01)
A61K 45/06 ^(2006.01) **A61P 35/02** ^(2006.01)

(48) Corrigendum issued on:

03.04.2024 Bulletin 2024/14

(52) Cooperative Patent Classification (CPC):

(C-Sets available)

A61P 35/02; A61K 31/155; A61K 31/366;**A61K 31/40; A61K 31/4706; A61K 45/06 (Cont.)**

(45) Date of publication and mention of the grant of the patent:

17.01.2024 Bulletin 2024/03

(86) International application number:

PCT/IB2022/052662(21) Application number: **22718776.2**

(87) International publication number:

WO 2022/201065 (29.09.2022 Gazette 2022/39)(22) Date of filing: **23.03.2022****(54) COMBINATION COMPRISING CHLOROQUINE, METFORMIN AND STATIN FOR MANAGEMENT OF CANCER, COMPOSITION AND METHODS THEREOF**

KOMBINATION MIT CHLOROQUIN, METFORMIN UND STATIN ZUR BEHANDLUNG VON KREBS,
 ZUSAMMENSETZUNG UND VERFAHREN DAFÜR

COMBINAISON COMPRENANT DE LA CHLOROQUINE, DE LA METFORMINE ET DE LA STATINE
 POUR LE TRAITEMENT DU CANCER, COMPOSITION ET MÉTHODES ASSOCIÉES

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
 PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

Designated Validation States:

KH MA MD TN

- **GROVER, Himanshu**

Delhi, 110085 (IN)

- **PATIL, Vivek**

Belgaum, Karnataka, 590017 (IN)

- **TYAGI, Anuj**

Bangalore, Karnataka, 560067 (IN)

- **KUMAR AGRAWAL, Ashish**

Bangalore, Karnataka, 560036 (IN)

- **KAPOOR, Shweta**

Bangalore, Karnataka, 560066 (IN)

- **MUNDKUR, Yatin**

Los Altos Hills, CA 94022 (US)(30) Priority: **23.03.2021 US 202163164828 P**

(43) Date of publication of application:

07.06.2023 Bulletin 2023/23(73) Proprietor: **Cellworks Group Inc.****San Jose, CA 95110 (US)**(74) Representative: **CMS Cameron McKenna Nabarro****Olswang LLP****Cannon Place****78 Cannon Street****London EC4N 6AF (GB)**

(72) Inventors:

- **KUMAR, Ansu**

Bangalore, Karnataka, 560066 (IN)

- **KHANDELWAL, Swati**

Bangalore, Karnataka, 560066 (IN)

- **MOHAPATRA, Subrat**

Bangalore, Karnataka, 560067 (IN)

(56) References cited:

WO-A2-2015/068142 EA-B1- 026 317**KR-A- 20060 092 428 US-A1- 2018 169 242****US-B2- 10 413 558**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 4 188 377 B8

- PRITHVIRAJ BOSE ET AL: "Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 25, no. 12, 31 October 2016 (2016-10-31), pages 1393-1403, XP055565134, UK ISSN: 1354-3784, DOI: 10.1080/13543784.2016.1250882

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/155, A61K 2300/00;

A61K 31/366, A61K 2300/00;

A61K 31/40, A61K 2300/00;

A61K 31/4706, A61K 2300/00